Oscar R Pozzi1, Michael R Zalutsky2. 1. Department of Radiology, Duke University Medical Center, Durham, NC, 27710, USA. Electronic address: oscarpozzi@hotmail.com. 2. Department of Radiology, Duke University Medical Center, Durham, NC, 27710, USA. Electronic address: zalut001@mc.duke.edu.
Abstract
INTRODUCTION: Alpha particles are radiation of high energy and short range, properties that can lead to radiolysis-mediated complications in labeling chemistry at the high radioactivity levels required for clinical application. In previous papers in this series, we have shown that radiation dose has a profound effect on the astatine species that are present in the labeling reaction and their suitability for the synthesis of N-succinimidyl 3-[211At]astatobenzoate. The purpose of this study was to evaluate the effects of adding N-chlorosuccinimide (NCS) to the methanol solution used for initial isolation of 211At after distillation, a process referred to as 211At stabilization, on 211At chemistry after exposure to high radiation doses. METHODS: High performance liquid chromatography was used to evaluate the distribution of 211At species present in methanol in the 500-65,000Gy radiation dose range and the synthesis of SAB from N-succinimidyl 3-(tri-n-butylstannyl)benzoate in the 500-120,000Gy radiation dose range using different 211At timeactivity combinations under conditions with/without 211At stabilization. RESULTS: In the absence of NCS stabilization, a reduced form of astatine, At(2), increased with increasing radiation dose, accounting for about half the total activity by about 15,000Gy, while with stabilization, At(2) accounted for <10% of 211At activity even at doses >60,000Gy. SAB yields without stabilization rapidly declined with increasing dose, falling to ~20% at about 5000Gy while with stabilization, yields >80% were obtained with 211At solutions stored for more than 23h and receiving radiation doses >100,000Gy. CONCLUSIONS: Adding NCS to the methanol solution used for initial isolation of 211At is a promising strategy for countering the deleterious effects of radiolysis on 211At chemistry. ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE: This strategy could facilitate the ability to perform 211At labeling at sites remote from its production and at the high activity levels required for clinical applications.
INTRODUCTION: Alpha particles are radiation of high energy and short range, properties that can lead to radiolysis-mediated complications in labeling chemistry at the high radioactivity levels required for clinical application. In previous papers in this series, we have shown that radiation dose has a profound effect on the astatine species that are present in the labeling reaction and their suitability for the synthesis of N-succinimidyl 3-[211At]astatobenzoate. The purpose of this study was to evaluate the effects of adding N-chlorosuccinimide (NCS) to the methanol solution used for initial isolation of 211At after distillation, a process referred to as 211At stabilization, on 211At chemistry after exposure to high radiation doses. METHODS: High performance liquid chromatography was used to evaluate the distribution of 211At species present in methanol in the 500-65,000Gy radiation dose range and the synthesis of SAB from N-succinimidyl 3-(tri-n-butylstannyl)benzoate in the 500-120,000Gy radiation dose range using different 211At timeactivity combinations under conditions with/without 211At stabilization. RESULTS: In the absence of NCS stabilization, a reduced form of astatine, At(2), increased with increasing radiation dose, accounting for about half the total activity by about 15,000Gy, while with stabilization, At(2) accounted for <10% of 211At activity even at doses >60,000Gy. SAB yields without stabilization rapidly declined with increasing dose, falling to ~20% at about 5000Gy while with stabilization, yields >80% were obtained with 211At solutions stored for more than 23h and receiving radiation doses >100,000Gy. CONCLUSIONS: Adding NCS to the methanol solution used for initial isolation of 211At is a promising strategy for countering the deleterious effects of radiolysis on 211At chemistry. ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE: This strategy could facilitate the ability to perform 211At labeling at sites remote from its production and at the high activity levels required for clinical applications.
Authors: Michael R Zalutsky; David A Reardon; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; Roger E McLendon; Terence Z Wong; Darell D Bigner Journal: J Nucl Med Date: 2007-12-12 Impact factor: 10.057
Authors: Ganesan Vaidyanathan; Oscar R Pozzi; Jaeyeon Choi; Xiao-Guang Zhao; Shawn Murphy; Michael R Zalutsky Journal: Cancer Biother Radiopharm Date: 2020-02-28 Impact factor: 3.099
Authors: Vandana Batra; Minu Samanta; Mehran Makvandi; David Groff; Paul Martorano; Jimmy Elias; Pietro Ranieri; Matthew Tsang; Catherine Hou; Yimei Li; Bruce Pawel; Daniel Martinez; Ganesan Vaidyanathan; Sean Carlin; Daniel A Pryma; John M Maris Journal: Clin Cancer Res Date: 2022-09-15 Impact factor: 13.801
Authors: Christoph Denk; Martin Wilkovitsch; Emma Aneheim; Matthias M Herth; Holger Jensen; Sture Lindegren; Hannes Mikula Journal: Chempluschem Date: 2019-04-04 Impact factor: 2.863